What does APOPHARMA do?

APOPHARMA is a pharmacy in Wezembeek-Oppem. Private Limited, started on 9 February 2005, 1 establishment.

What is the address of APOPHARMA?

The registered office of APOPHARMA is located at Louis Marcelisstraat 126, 1970 Wezembeek-Oppem.

Is APOPHARMA still active?

Yes. According to the CBE (17 September 2026) APOPHARMA is active, legal situation “Normale toestand”, started on 9 February 2005.

Is APOPHARMA registered on Peppol?

Yes, APOPHARMA is registered on the Peppol network with ID 0208:0871799376.

What is the enterprise number of APOPHARMA?

The enterprise number of APOPHARMA is BE0871799376.

When was APOPHARMA founded?

APOPHARMA was founded on 9 February 2005.

The shares are held by F.L. INVEST (100%).

Is APOPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 February 2005; 4 annual accounts filed, latest fiscal year 2024.

How much profit did APOPHARMA make in 2024?

APOPHARMA posted a profit after taxes of € 193,039 in financial year 2024.

What is the revenue of APOPHARMA?

As a small company, APOPHARMA is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 222,930.

How much does an employee at APOPHARMA earn?

The average wage cost per full-time employee at APOPHARMA was € 27,900 in 2021: staff costs of € 27,913 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

APOPHARMA (Private Limited) - Wezembeek-Oppem

Dossier APOPHARMA, printed on 17 September 2026 from databakkes.be/en/0871799376/apopharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2024

APOPHARMA from Wezembeek-Oppem, company number BE0871799376, closed financial year 2024 with a result of € 193,039 after tax. For that financial year APOPHARMA recorded a gross margin of € 222,930 and equity of € 169,405. Compared with financial year 2023, the result moved from € 274,573 to € 193,039. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 29, 2025.

What it is worth Growing

€ 169,405

▲ 2% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 193,039

▼ 30% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 417,353

▲ 53% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € 59,405.

People and assets in 2024

Vehicles and equipment

€ 1,045

▼ 57% vs 2023

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt

€ 25,160

▲ € 24,807 vs 2023

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 87,306

▲ 260% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Revenue	-	-	€ 1,068,638 Revenue 2023: € 1,068,638 First fiscal year in the series	-
Gross margin	€ 292,386 Gross margin 2021: € 292,386 First fiscal year in the series	€ 270,067 Gross margin 2022: € 270,067 ▼ 8% vs 2021 (€ 292,386) Unfavourable step	€ 280,230 Gross margin 2023: € 280,230 ▲ 4% vs 2022 (€ 270,067) Favourable step	€ 222,930 Gross margin 2024: € 222,930 ▼ 20% vs 2023 (€ 280,230) Unfavourable step	▼ 20%
Profit after taxes	€ 256,416 Profit after taxes 2021: € 256,416 First fiscal year in the series	€ 263,734 Profit after taxes 2022: € 263,734 ▲ 3% vs 2021 (€ 256,416) Favourable step	€ 274,573 Profit after taxes 2023: € 274,573 ▲ 4% vs 2022 (€ 263,734) Favourable step	€ 193,039 Profit after taxes 2024: € 193,039 ▼ 30% vs 2023 (€ 274,573) Unfavourable step	▼ 30%
Equity	€ 158,058 Equity 2021: € 158,058 First fiscal year in the series	€ 161,793 Equity 2022: € 161,793 ▲ 2% vs 2021 (€ 158,058) Favourable step	€ 166,365 Equity 2023: € 166,365 ▲ 3% vs 2022 (€ 161,793) Favourable step	€ 169,405 Equity 2024: € 169,405 ▲ 2% vs 2023 (€ 166,365) Favourable step	▲ 2%
Total debts	€ 469,403 Total debts 2021: € 469,403 First fiscal year in the series	€ 488,230 Total debts 2022: € 488,230 ▲ 4% vs 2021 (€ 469,403) Unfavourable step	€ 352,396 Total debts 2023: € 352,396 ▼ 28% vs 2022 (€ 488,230) Favourable step	€ 466,073 Total debts 2024: € 466,073 ▲ 32% vs 2023 (€ 352,396) Unfavourable step	▲ 32%
Cash	€ 337,140 Cash 2021: € 337,140 First fiscal year in the series	€ 263,717 Cash 2022: € 263,717 ▼ 22% vs 2021 (€ 337,140) Unfavourable step	€ 273,111 Cash 2023: € 273,111 ▲ 4% vs 2022 (€ 263,717) Favourable step	€ 417,353 Cash 2024: € 417,353 ▲ 53% vs 2023 (€ 273,111) Favourable step	▲ 53%
Retained profit	€ 48,058 Retained profit 2021: € 48,058 First fiscal year in the series	€ 51,793 Retained profit 2022: € 51,793 ▲ 8% vs 2021 (€ 48,058) Favourable step	€ 56,365 Retained profit 2023: € 56,365 ▲ 9% vs 2022 (€ 51,793) Favourable step	€ 59,405 Retained profit 2024: € 59,405 ▲ 5% vs 2023 (€ 56,365) Favourable step	▲ 5%
Dividend	€ 245,000 Dividend 2021: € 245,000 First fiscal year in the series	€ 260,000 Dividend 2022: € 260,000 ▲ 6% vs 2021 (€ 245,000) Unchanged	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 260,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 0 Bank debt 2021: € 0 First fiscal year in the series	€ 0 Bank debt 2022: € 0 Unchanged (€ 0) Unchanged	€ 353 Bank debt 2023: € 353 Unchanged (€ 0) Unfavourable step	€ 25,160 Bank debt 2024: € 25,160 ▲ € 24,807 vs 2023 (€ 353) Unfavourable step	▲ € 24,807
Balance sheet total	€ 627,461 Balance sheet total 2021: € 627,461 First fiscal year in the series	€ 650,022 Balance sheet total 2022: € 650,022 ▲ 4% vs 2021 (€ 627,461) Unchanged	€ 518,761 Balance sheet total 2023: € 518,761 ▼ 20% vs 2022 (€ 650,022) Unchanged	€ 635,478 Balance sheet total 2024: € 635,478 ▲ 22% vs 2023 (€ 518,761) Unchanged	▲ 22%
Employees (FTE)	1 Employees (FTE) 2021: 1 First fiscal year in the series	-	-	-

Key figures of APOPHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to APOPHARMA?

What happened at APOPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 29, 2025 New annual accounts for financial year 2024: profit of € 193,039 (▼ 30% vs 2023). filed late Source: NBB ↗
Feb 9, 2005 Start of the company according to the CBE. KBO
Feb 1, 1985 New establishment in Wezembeek-Oppem. KBO

In short

From € 256,416 profit in 2021 to € 193,039 profit in 2024.

Paid € 9,528 in corporate taxes since 2021.

Best year ever: 2023, with € 274,573 profit.

On average € 292,400 of value added per employee in 2021.

Original PDFs at the National Bank ↗

A new publication or filing at APOPHARMA? We notify you, reason included.

Follow APOPHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Louis Marcelisstraat 126

1970 Wezembeek-Oppem

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0871.799.376

VAT number

BE 0871.799.376

Registered office

Louis Marcelisstraat 126, 1970 Wezembeek-Oppem

Names & denominations

APOPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

9 February 2005

Peppol

Active · Active since 17 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗